LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Guardant Health Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

106.42 3.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

99.96

Max

107.64

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.7B

14B

Ankstesnė atidarymo kaina

102.81

Ankstesnė uždarymo kaina

106.42

Naujienos nuotaikos

By Acuity

50%

50%

149 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-11 23:47; UTC

Karštos akcijos

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026-02-11 22:59; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Grab Holdings to Buy U.S.-Based Stash Financial

2026-02-11 23:54; UTC

Uždarbis

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026-02-11 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026-02-11 23:49; UTC

Uždarbis

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026-02-11 23:45; UTC

Uždarbis

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026-02-11 23:42; UTC

Uždarbis

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026-02-11 23:41; UTC

Uždarbis

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026-02-11 23:40; UTC

Uždarbis

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026-02-11 23:35; UTC

Rinkos pokalbiai

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026-02-11 23:18; UTC

Rinkos pokalbiai

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026-02-11 23:14; UTC

Rinkos pokalbiai

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026-02-11 22:58; UTC

Uždarbis

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026-02-11 22:57; UTC

Uždarbis

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026-02-11 22:54; UTC

Uždarbis

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026-02-11 22:53; UTC

Uždarbis

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:23; UTC

Uždarbis

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026-02-11 22:19; UTC

Uždarbis

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026-02-11 22:16; UTC

Uždarbis

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

21.82% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  21.82%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

149 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat